Casdin Capital Overview
- Investor Type
-
Hedge Fund
- Status
-
Active
- Professionals
-
6
- Investments
-
234
- Portfolio
-
110
- Exits
-
71
Casdin Capital General Information
Description
Founded in 2012, Casdin Capital is a hedge fund manager based in New York, New York. The firm seeks to make venture capital investments in companies operating in the biotechnology, healthcare, life science, information technology, and industrial sectors across the United States. The firm primarily focuses on small and medium-sized market equity investments.
Contact Information
Website
www.casdincapital.com
Year Founded
2012
Investor Status
Actively Seeking New Investments
Primary Investor Type
Hedge Fund
Other Investor Types
Growth/Expansion
Venture Capital
Primary Office
- 1350 Avenue of the Americas
- Suite 2600
- New York, NY 10019
- United States
+1 (212) 000-0000
Casdin Capital Investments (234)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Company Stage | Lead Partner |
|---|---|---|---|---|---|---|
| iVexSol | 26-Jan-2023 | Later Stage VC | 000.00 | Discovery Tools (Healthcare) | Generating Revenue | |
| 0000 00000000 | 10-Jan-2023 | 0000 00000 | 00.00 | Other Healthcare Technology Systems | Generating Revenue | |
| 000000 | 05-Jan-2023 | 00000 00000 | 00000 | Other Healthcare Technology Systems | Generating Revenue | |
| 000000 000000 | 08-Dec-2022 | 00000 00000 | 00.00 | Other Commercial Products | Stealth | |
| 000000000 | 17-Nov-2022 | 00000 00000 | 00000 | Drug Discovery | Generating Revenue | |
| 0000 000 | 10-Oct-2022 | 00000 00000 | 000.00 | Other Healthcare Technology Systems | Generating Revenue | 00000 000000000 00.0 |
| 000000000 00000000 | 21-Sep-2022 | 00000 00000 | 000.00 | Biotechnology | Generating Revenue | |
| 00000000000000 | 08-Sep-2022 | 00000 00000 | 0000 | Other Healthcare Services | Generating Revenue | 000 000000 |
| Meiogenix | 18-Aug-2022 | Later Stage VC | 000.00 | Biotechnology | Generating Revenue/Not Profitable | |
| Structure Therapeutics | 01-Aug-2022 | Later Stage VC | 00000 | Drug Discovery | Clinical Trials - Phase 2 |
Casdin Capital Exits (71)
| Company Name | Exit Date | Exit Type | Exit Size |
|---|---|---|---|
| Prime Medicine | 20-Oct-2022 | IPO | 00000 |
| 0000000000 | 31-Aug-2022 | 000000000000000000 | 000.00 |
| 00000 | 21-Jul-2022 | 000 | 0000 |
| 00000000 | 14-Jul-2022 | 0000000000: 000000 | |
| 00000000 000000000 | 16-Jun-2022 | 000000000 00000000 | |
| 000000 00000000000 | 08-Feb-2022 | 000000000000000000 | 00.000 |
| 000000 | 30-Dec-2021 | 000000 0000000000 | 0000 |
| 000000000 000000 | 10-Dec-2021 | 000 | 000.00 |
| LianBio | 01-Nov-2021 | IPO | 00000 |
| Exscientia | 01-Oct-2021 | IPO | 00000 |
Casdin Capital Investments by Industry, Year, and Region
Investments by Industry
Investments by Year
Investments by Region
Casdin Capital Team (21)
| Name | Title | Deals | Funds | Boards | Office |
|---|---|---|---|---|---|
| Lawrence Canzoneri | Chief Financial Officer | New York, NY | |||
| Alexandria Fisk | Chief Operating Officer | New York, NY | |||
| Angelo Crupi | Chief Compliance Officer | New York, NY | |||
| Eli Casdin | Founder & Chief Investment Officer | 00 | 0 | 00 | New York, NY |
| Randy White | Director, Business Development | New York, NY |
Casdin Capital Co-Investors (585)
| Name | With | Exits | Lead Partner | Series | Industry |
|---|---|---|---|---|---|
| GV | 24 | 0 |
|
|
|
| Alexandria Venture Investments | 00 | 0 | 0 |
|
|
| Perceptive Advisors | 00 | 0 | 0 |
|
|
| Nextech Invest | 00 | 0 | 0 |
|
|
| The Invus Group | 00 | 0 | 0 |
|
|